{
    "doi": "https://doi.org/10.1182/blood.V110.11.2077.2077",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=900",
    "start_url_page_num": 900,
    "is_scraped": "1",
    "article_title": "The Cytofluorimetric/FISH Diagnostic Approach Define a B-Cell Variant-CLL with Peculiar Clinico-Biological Features. ",
    "article_date": "November 16, 2007",
    "session_type": "CLL - Biology and Pathophysiology, excluding Therapy",
    "topics": [
        "blood platelets",
        "b-lymphocytes",
        "brachial plexus neuritis",
        "cd20 antigens",
        "cd23 antigen",
        "cd38",
        "chemotherapy regimen",
        "chromosome abnormality",
        "chronic lymphocytic leukemia",
        "doubling time"
    ],
    "author_names": [
        "Lilla Cro",
        "Luca Baldini",
        "Lucia Nobili",
        "Antonino Neri",
        "Nadia Zucal",
        "Andrea Ferrario",
        "Marta Lionetti",
        "Francesco Bertoni",
        "Fortunato Morabito",
        "Andrea Guffanti",
        "Maria Goldaniga",
        "Giovanna Cutrona",
        "Agostino Cortelezzi",
        "Stefano Luminari8",
        "Manlio Ferrarini",
        "Giorgio Lambertenghi Deliliers"
    ],
    "author_affiliations": [
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Experimental Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Experimental Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "UO Ematologia, AO Cosenza, Cosenza, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Divisione Medicina I, Ospedale Fatebenefratelli e Oftalmico, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "UO Oncologia Medica C, INRC, Genova, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Dipartimento di Oncologia e Ematologia, Universita degli Studi di Modena e Reggio Emilia, Modena, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Dipartimento di Oncologia e Ematologia, Universita degli Studi di Modena e Reggio Emilia, Modena, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ],
        [
            "Centro di Genetica Molecolare, Ospedale Maggiore Policlinico MaRe, Milan, Italy",
            "UO Ematologia 1, Ospedale Maggiore Policlinico MaRe, Milan, Italy"
        ]
    ],
    "first_author_latitude": "45.45884170000001",
    "first_author_longitude": "9.1949702",
    "abstract_text": "In the present study, we describe the clinico-biological features of 63 cases of variant B-CLL (v-B-CLL) defined according to a previously described diagnostic algorithm for CD5+ mature B-cell leukemias, based on the combined use of Cytofluorimetric (CFM) analysis and t(11;14)(q13;q32) detection by means of fluorescence in situ hybridisation (FISH). These leukemias were characterized by SIg bright /CD23 + or CD23 +/\u2212 , CD79b/CD20 bright, and negativity for t(11;14)(q13;q32). A historical series of 112 classical B-CLL was used as comparison. The mean age was 61 years (33\u201385) and M/F ratio 1.9. The v-B-CLL cases were significantly different from the B-CLL cases in terms of the following clinico-hematological variables: age <70 yrs, lymphocytosis <20 \u00d710 9 /L (P <.0001), lymphocyte doubling time \u2264 12 months (P=.04), high serum \u00df2-microglobulin levels (P=.003) and presence of splenomegaly (P=.007). No differences were found in terms of sex, Hb levels, platelets count, presence of serum monoclonal component, serum LDH levels and HCV-Ab positivity. In v-B-CLL and B-CLL pts the median follow-up was respectively 56 and 84 months. The median overall survival was 80 months in v-B-CLL pts while it was not reached in B-CLL pts; 37 pts (58.7%) in the first group started chemotherapy vs 84 pts (56.4%) in the latter. The analysis of leukemic cell biological characteristics related to the prognosis was also made in part of the cases. A classic or mixed-CLL cytomorphology was seen only in 22/61 pts (36.1%). The percentage of CD38 positive cases was higher in v-B-CLL (60.3) than in B-CLL (44.6; P=.028); the IgV H mutation status, evaluated in 30/63 cases, was more frequently hypermutated in v-B-CLL group (23/30) than B-CLL (P=.03); the percentage of CFM Zap-70 positivity, evaluated in 42/63 cases, was similar in two groups (47.6 vs 57.4%, respectively). Interestingly, significant differences were found about the frequence of the recurrent chromosome alterations, evaluated in 48/63 cases, by means of FISH analysis: trisomy 12 was more frequent in v-B-CLL (37.5 vs 18.4%, p=0.02), while del13q14 was more frequent in B-CLL (14.5 vs 37.8%, P=0.007). In both groups, del 11q22.3 and del 17p13.1 were relatively rare (4 vs 8%, and 2 vs 7.7%, respectively). In conclusion, our study identifies, on the basis of a defined CFM-FISH diagnostic approach, a variant form of B-CLL that shows significant differences in terms of genetic and clinical features."
}